BLTE News and Press, Belite Bio Inc From 08/22/22

LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing The Phase 3, Multi-center, Randomized, D ...

The following slide deck was published by Belite Bio, Inc in conjunction with their 2022 Q2 earnings call. For further details see: Belite Bio, Inc 2022 Q2 - Results - Earnings Call Presentation

Belite Bio, Inc (BLTE) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Tom Lin – Chief Executive Officer Nathan Mata – Chief Scientific Officer Hao-Yuan Chuang – Chief Financial Officer Conference Call P...

Belite Bio press release ( NASDAQ: BLTE ): 1H GAAP EPS of -$0.23 beats by $0.05 . As of June 30, 2022, the company had $48.7M in cash. For further details see: Belite Bio GAAP EPS of -$0.23 beats by $0.05

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, today announced its financial results for the first six months ended June 30, 2022 and provi...

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss th...

Gainers: Direct Digital Holdings ( DRCT ) +81% . ToughBuilt Industries ( TBLT ) +54% . Stronghold Digital Mining ( SDIG ) +42% . Calithera Biosciences ( CALA ) +27% . CorMedix ( CRMD ) +23% . Allakos ( ALLK ) +22% ...

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...

Belite Bio ( NASDAQ: BLTE ) on Tuesday said it had submitted an investigational new drug application to the U.S. FDA to proceed with its phase 3 trial of its oral tablet LBS-008 for the treatment of Stargardt disease (STGD1). STGD1 is a rare genetic eye disease that is...

LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1) There are currently no approved treatments for STGD1 Approximately 30,000 patients in the U.S. suffer from STGD1 A 2-year Phase 2 trial in adolescent...